New FDA Guidance Helps Industry Develop Cell-Based Viral Vaccines
The US Food and Drug Administration (FDA) issued a new guidance September 28 to help manufacturers develop safe and effective cell-based viral vaccines.
The US Food and Drug Administration (FDA) issued a new guidance September 28 to help manufacturers develop safe and effective cell-based viral vaccines. FDA's goal is to facilitate the development of vaccines, including those to address emerging and pandemic threats.
Entitled "Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases," the guidance updates recommendations in the 1993 document, "Points to Consider in the Characterization of Cell Lines Used to Produce Biologics."
The updated guidance provides information for determining the suitability of a cell culture for manufacturing, as well as for testing and validating the safety and purity of the cells used to develop and produce viral vaccines. It also provides information on testing at different production stages, and describes quality-control test methods for cell substrate and adventitious agent issues.
“This is a propitious time for a new guidance,” says Philip Krause, MD, Deputy Director of the Division of Viral Products of the Office of Vaccines.
”There has been an expansion of the kinds of cells manufacturers are considering for use in vaccine manufacture, and there have also been improvements in the technology for testing cells,” he says.
The new document is timely for another reason, too. Demands for influenza vaccine will surely be rising, as flu season approaches; it is easier to scale up cell-based vaccines, than it is egg-based vaccines, if and when surge capacity is needed. Cells, unlike eggs, can be frozen for staroage and then thawed when needed.
Unlike the previous document, according to Krause, the new guidance offers a lot of scientific rationale for recommendations and provides the underlying principles for why they are made. This helps manufacturers think about how to address issues associated with cells used in vaccine manufacture.
Basically, says Krause, it compiles into one place long-standing methods and recommendations about vaccine development. The guidance is available at: www.fda.gov/cber/gdlns/vaccsubstrates.pdf
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
